REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA POST AUTOLOGOUS STEM-CELL TRANSPLANTATION

被引：0
作者：
Zagadailov, E. A. [1 ]
Corman, S. [2 ]
Hagan, M. [3 ]
Chirikov, V. [2 ]
Johnson, C. [2 ]
Macahilig, C. [3 ]
Sea, B. [1 ]
Dalal, M. R. [1 ]
Broeckelmann, P. J. [4 ,5 ]
Illidge, T. [6 ]
机构：
[1] Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Pharmerit Int, Bethesda, MD USA
[3] Med Data Analyt, Parsippany, NJ USA
[4] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[5] Univ Hosp Cologne, GHSG, Cologne, Germany
[6] Univ Manchester, Inst Canc Sci, Christie Hosp, Manchester, Lancs, England
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P094
引用
收藏
页码：51 / 51
页数：1
相关论文
共 50 条
  • [41] Response to Brentuximab Vedotin and Quality of Life in Patients with Relapsed/Refractory Hodgkin Lymphoma (RR HL) in the Real World Setting
    Ionova, Tatyana
    Afanasiev, Boris
    Andrievskih, Maria
    Amdiev, Alim
    Baryakh, Elena A.
    Chang, Viktor
    Husainova, Gulnara
    Ivanov, Vladimir
    Kaplanov, Kamil D.
    Kaverina, Oksana
    Klitochenko, Tatiana
    Kurakin, Vyacheslav
    Larionova, Olga
    Lazareva, Darya
    Lepik, Kirill
    Lysenko, Irina
    Mikhailova, Nataliia
    Minullina, Raisa
    Mironov, Oleg
    Misyurina, Elena
    Mochkin, Nikita
    Nikitina, Tatiana
    Osipov, Iurii
    Petrova, Tatiana
    Porfirieva, Natalia
    Rykavitcin, Oleg
    Safin, Rustem
    Shelekhova, Tatiana
    Sherstnev, Dmitrij
    Simashova, Polina
    Smirnova, Elena
    Trenina, Natalia
    Vasiliev, Evgeniy V.
    Volkov, Mikhail
    Volodicheva, Elena
    [J]. BLOOD, 2019, 134
  • [42] BRENTUXIMAB VEDOTIN IN PATIENTS WHO ARE INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: A UNITED KINGDOM AND GERMANY RETROSPECTIVE STUDY
    Broeckelmann, P. J.
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Seal, B.
    Dalal, M. R.
    Illidge, T.
    [J]. HAEMATOLOGICA, 2016, 101 : 50 - 51
  • [43] Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study
    Broeckelmann, Paul J.
    Zagadailov, Erin A.
    Corman, Shelby L.
    Chirikov, Viktor
    Johnson, Courtney
    Macahilig, Cynthia
    Seal, Brian
    Dalal, Mehul R.
    Illidge, Tim
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (06) : 553 - 558
  • [44] Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant
    Karuturi, Meghan S.
    Arai, Sally
    Chen, Robert W.
    Gopal, Ajay K.
    Feng, Lei
    Yuan, Ying
    Smith, Scott E.
    Ansell, Stephen M.
    Rosenblatt, Joseph D.
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Bartlet, Nancy L.
    Cheson, Bruce D.
    Forero-Torres, Andres
    Moskowitz, Craig H.
    Connors, Joseph M.
    Fanale, Michelle A.
    de Vos, Sven
    Engert, Andreas
    Illidge, Tim
    Borchmann, Peter
    Morschhauser, Franck
    Horning, Sandra J.
    Younes, Anas
    [J]. BLOOD, 2012, 120 (21)
  • [45] COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
    Woods, B.
    Thompson, J.
    Barcena, L.
    Liu, Y.
    Huang, H.
    Martinez, C.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A509 - A509
  • [46] POST TRANSPLANT OUTCOMES IN A MULTICENTER PHASE II STUDY OF BRENTUXIMAB VEDOTIN AS FIRST LINE SALVAGE THERAPY IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION
    Herrera, A.
    Palmer, J.
    Martin, P.
    Armenian, S.
    Tsai, N. -C.
    Mott, M.
    Sahebi, F.
    Cai, J. -L.
    Siddiqi, T.
    Popplewell, L.
    Nademanee, A.
    Rosen, S.
    Kwak, L.
    Forman, S.
    Chen, R.
    [J]. HAEMATOLOGICA, 2016, 101 : 47 - 48
  • [47] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma
    Fernandez, Laura Lorente
    Dominguez, Samuel Romero
    Mari, Asuncion Albert
    Benito, Esperanza Nunez
    Briz, Eduardo Lopez
    Andres, Jose Luis Poveda
    [J]. FARMACIA HOSPITALARIA, 2025, 49 (01) : T17 - T23
  • [48] Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma
    Garciaz, Sylvain
    Coso, Diane
    Peyrade, Frederic
    Fuerst, Sabine
    Duran, Segolene
    Chetaille, Bruno
    Brenot-Rossi, Isabelle
    Devillier, Raynier
    Granata, Angela
    Blaise, Didier
    Bouabdallah, Reda
    [J]. HEMATOLOGICAL ONCOLOGY, 2014, 32 (04) : 187 - 191
  • [49] Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma
    Sirohi, B.
    Cunningham, D.
    Powles, R.
    Murphy, F.
    Arkenau, T.
    Norman, A.
    Oates, J.
    Wotherspoon, A.
    Horwich, A.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (07) : 1312 - 1319
  • [50] Low-Dose Nivolumab Plus Brentuximab Vedotin As a Bridge to Stem Cell Transplantation in Relapsed/Refractory Classical Hodgkin Lymphoma
    Colunga-Pedraza, Panelperla R. R.
    Ulises Coronado-Alejandro, Edgar
    De La Garza, Fernando
    Gomez Gomez, Eliezer Tomas
    Gomez-De Leon, Andres
    Colunga Pedraza, Julia Esther
    Homero Gutierrez-Aguirre, Cesar
    Cantu Rodriguez, Olga Graciela
    Gomez-Almaguer, David
    [J]. BLOOD, 2021, 138
12345